156 related articles for article (PubMed ID: 11489832)
1. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
Casado E; Gomez-Navarro J; Yamamoto M; Adachi Y; Coolidge CJ; Arafat WO; Barker SD; Wang MH; Mahasreshti PJ; Hemminki A; Gonzalez-Baron M; Barnes MN; Pustilnik TB; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 2001 Aug; 7(8):2496-504. PubMed ID: 11489832
[TBL] [Abstract][Full Text] [Related]
2. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
[TBL] [Abstract][Full Text] [Related]
3. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
Wesseling JG; Yamamoto M; Adachi Y; Bosma PJ; van Wijland M; Blackwell JL; Li H; Reynolds PN; Dmitriev I; Vickers SM; Huibregtse K; Curiel DT
Cancer Gene Ther; 2001 Dec; 8(12):990-6. PubMed ID: 11781662
[TBL] [Abstract][Full Text] [Related]
4. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors.
Adachi Y; Reynolds PN; Yamamoto M; Grizzle WE; Overturf K; Matsubara S; Muramatsu T; Curiel DT
Cancer Res; 2000 Aug; 60(16):4305-10. PubMed ID: 10969765
[TBL] [Abstract][Full Text] [Related]
5. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
6. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
7. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2002 Feb; 84(2):228-34. PubMed ID: 11812079
[TBL] [Abstract][Full Text] [Related]
8. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers.
Yamamoto M; Alemany R; Adachi Y; Grizzle WE; Curiel DT
Mol Ther; 2001 Mar; 3(3):385-94. PubMed ID: 11273781
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Barker S; Yamaoto M; Li F; Alvarez RD; Curiel DT
Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
[TBL] [Abstract][Full Text] [Related]
12. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
14. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract][Full Text] [Related]
15. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
[TBL] [Abstract][Full Text] [Related]
16. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter.
Berry NB; Cho YM; Harrington MA; Williams SD; Foley J; Nephew KP
Gynecol Oncol; 2004 Mar; 92(3):896-904. PubMed ID: 14984958
[TBL] [Abstract][Full Text] [Related]
18. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
19. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.
Selvakumaran M; Bao R; Crijns AP; Connolly DC; Weinstein JK; Hamilton TC
Cancer Res; 2001 Feb; 61(4):1291-5. PubMed ID: 11245422
[TBL] [Abstract][Full Text] [Related]
20. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
Kanerva A; Bauerschmitz GJ; Yamamoto M; Lam JT; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
Gene Ther; 2004 Mar; 11(6):552-9. PubMed ID: 14999227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]